• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
      • Project Deliverables
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • For Research Participants
    • Why Participate in EPAD?
      • EPAD & Dementia Research
      • Our Progress
    • Participation in EPAD Trials
    • EPAD Cohort Study
      • Trial Locations
      • EPAD Study Visits
    • EPAD Stories
    • Participation FAQs
  • For Intervention Owners
    • The EPAD Platform
      • Terms of Reference
    • EPAD Benefits
    • Clinical Candidate Selection
      • EPAD Application Process
    • EPAD FAQs
    • Research Resources
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Events
Menu back  

Congratulations to Geneva University, the EPAD Trial Delivery Centre of the Month

2018-05-04News

We are delighted to announce that April was the most successful month to date with 73 new research participants enrolled in the EPAD Longitudinal Cohort Study. We continued the positive trend in recruitment of research participants by exceeding the 66 research participants enrolled in March and the 53 in February.

Congratulations are due to Université de Genève (Geneva, Switzerland) as the most successful trial delivery centre of the month screening 14 research participants in April for their inclusion in the EPAD study. According to Prof Giovanni Frisoni, principal investigator of the Geneva team: “EPAD is piloting the future. A future when Alzheimer’s will not be treated when memory symptoms are already established, but risk will be detected in the population, high risk persons will be identified and treated with drugs that will decrease the risk.”

Congratulations to the team of Giovanni Frisoni (pictured on the right) and his colleagues Frédéric Assal, Aline Mendes, Maura Parapini (second from right), Zyka Selimi (first from left), Lucas Sveitaka, Christine Trombert (third from left) and Coralie Vuilloud (second from left).

The EPAD family of trial delivery centres also grew to 15 sites in April with Hôpital Pitié Salpêtrière – AP-HP (Paris, France) and West London Mental Health (London, United Kingdom) both enrolling their first research participants.

Add to this that, in April, we reached the milestone of 600 screened research participants and we hope that you will share our positive assessment of the continuing progress of this exciting research collaboration. Stay tuned for more news in June.

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
Interview with Sammy Danso
2019-01-24
Interview with Marija Jovanovic
2019-01-24
Spotlight on Grampian
2019-01-24
Interview with Alejandro Laquidain
2019-01-17
EPAD turns four!
2019-01-15
EPAD publishes its LCS study protocol
2018-12-27
Latest News
  • Interview with Sammy Danso
    2019-01-24
  • Interview with Marija Jovanovic
    2019-01-24
  • Spotlight on Grampian
    2019-01-24
  • Interview with Alejandro Laquidain
    2019-01-17
  • EPAD turns four!
    2019-01-15
Subscribe to our Newsletter

View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

"I hope that the #EPADAcademy will become a close circle of #researchers who will be providing support to nourish a new generation of academics in the field of #dementia" said #EPADFellow @stina_saunders Check out the newly #EPADAcademy tab on our website: ep-ad.org/epad-academy/ pic.twitter.com/8xRBkuDL3l

reply retweet favorite
10:02 am · 2019-02-19
Twitter
EPAD
EPAD
@IMI_EPAD

Who are we and what are we doing? Read recent interviews with #epadistas on our website to find out more: ep-ad.org/news-publicati… pic.twitter.com/cOp2eueOpa

reply retweet favorite
9:49 am · 2019-02-19
Twitter
EPAD
EPAD
@IMI_EPAD

Happy to inform that Deliverable D1.6 "Interim report on evaluation of #biomarker and #clinical #assessments and #outcomes from existing and acquired #data" was submitted to @IMI_JU last month. ep-ad.org/about/project-… pic.twitter.com/SgyZMYXA7q

reply retweet favorite
7:49 am · 2019-02-18
Twitter
EPAD
EPAD
@IMI_EPAD

José Luis Molinuevo (@fpmaragall) mentioned @IMI_EPAD in this spanish report published in the newspaper El País. "We participate in the EPAD project, a consortium between the academic and the private sector to design more efficient Phase II trials" elpais.com/elpais/2019/02… twitter.com/fpmaragall/sta…

reply retweet favorite
10:00 am · 2019-02-14
Twitter
EPAD
EPAD
@IMI_EPAD

.@IMI_EPAD Longitudinal Cohort Study recruitment Update ⤵️ We currently have 21 European sites enrolling and 1450 research participants screened. @IMI_JU @EFPIA @EU_H2020

reply retweet favorite
8:27 am · 2019-02-13
Copyright © 2015-19 EPAD | Created by CMAST and Aridhia
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More